Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme [clinicaltrials:NCT00021307]
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme [clinicaltrials:NCT00021307]
Bio2RDF identifier
NCT00021307
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00021307
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... rent glioblastoma multiforme.
brief title [clinicaltrials_vocabulary:brief-title]
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2002-04-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES: I. Determin ...... d for phase II of this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2001-07-11T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
adult giant cell glioblastoma
adult glioblastoma
adult gliosarcoma
recurrent adult brain tumor
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2013-07-10T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00021307
official title [clinicaltrials_vocabulary:official-title]
Phase I/II Trial Of Temozolomide And Carboplatin In Recurrent Glioblastoma Multiforme
org study id [clinicaltrials_vocabulary:org-study-id]
FCCC-01004
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2002-04-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
CDR0000068768
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2013-07-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
Study not activated.
identifier
clinicaltrials:NCT00021307
title
Temozolomide Plus Carboplatin in Treating Patients With Recurrent Glioblastoma Multiforme
@en
type
label
Temozolomide Plus Carboplatin ...... e [clinicaltrials:NCT00021307]
@en